EAM
Erste Asset Management Portfolio holdings
AUM
$11.9B
1-Year Return
22.95%
This Quarter Return
+7.94%
1 Year Return
+22.95%
3 Year Return
+112.82%
5 Year Return
+205.55%
10 Year Return
–
AUM
$4.09B
AUM Growth
+$472M
(+13%)
Cap. Flow
+$286M
Cap. Flow
% of AUM
6.99%
Top 10 Holdings %
Top 10 Hldgs %
16.99%
Holding
924
New
29
Increased
201
Reduced
78
Closed
20
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
+$19.5M |
| 2 |
Applied Materials
AMAT
|
+$18.9M |
| 3 |
Parker-Hannifin
PH
|
+$17M |
| 4 |
NVIDIA
NVDA
|
+$15.7M |
| 5 |
VMW
VMware, Inc
VMW
|
+$15.1M |
Top Sells
| 1 |
ON Semiconductor
ON
|
+$45.8M |
| 2 |
Tapestry
TPR
|
+$12.4M |
| 3 |
Blackrock
BLK
|
+$11.6M |
| 4 |
Intercontinental Exchange
ICE
|
+$10.6M |
| 5 |
Amphenol
APH
|
+$10.4M |
Sector Composition
| 1 | Technology | 27.94% |
| 2 | Healthcare | 19.38% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Industrials | 10.12% |
| 5 | Financials | 8.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CCXI
226
DELISTED
ChemoCentryx, Inc.
CCXI
| $2.99M | 0.07% |
60,000
| – | – |
|
227
NetEase
NTES
$91.1B
| $2.98M | 0.07% |
29,000
| – | – |
|
228
FibroGen
FGEN
$46.4M
| $2.9M | 0.07% |
3,732
| – | – |
|
|
XLRN
229
DELISTED
Acceleron Pharma Inc.
XLRN
| $2.87M | 0.07% |
21,600
+5,500
| +34% | +$732K |
|
230
Voyager Therapeutics
VYGR
$222M
| $2.81M | 0.07% |
592,900
+205,000
| +53% | +$970K |
|
231
eBay
EBAY
$42.2B
| $2.8M | 0.07% |
46,400
+3,400
| +8% | +$205K |
|
232
VF Corp
VFC
$5.95B
| $2.77M | 0.07% |
34,600
| – | – |
|
233
Whirlpool
WHR
$5.24B
| $2.76M | 0.07% |
12,510
+460
| +4% | +$101K |
|
234
Labcorp
LH
$23.1B
| $2.75M | 0.07% |
12,629
+8,555
| +210% | +$1.86M |
|
235
Toronto Dominion Bank
TD
$129B
| $2.68M | 0.07% |
40,800
+2,200
| +6% | +$145K |
|
236
Berkshire Hathaway Class B
BRK.B
$1.06T
| $2.64M | 0.06% |
10,242
+4,760
| +87% | +$1.23M |
|
237
Acadia Pharmaceuticals
ACAD
$4.19B
| $2.61M | 0.06% |
101,500
| – | – |
|
|
PRAH
238
DELISTED
PRA Health Sciences, Inc.
PRAH
| $2.6M | 0.06% |
16,900
| – | – |
|
239
Nutanix
NTNX
$20.3B
| $2.59M | 0.06% |
100,000
| – | – |
|
|
BPMC
240
DELISTED
Blueprint Medicines
BPMC
| $2.57M | 0.06% |
27,600
| – | – |
|
|
CTXS
241
DELISTED
Citrix Systems Inc
CTXS
| $2.56M | 0.06% |
18,534
+2,500
| +16% | +$346K |
|
242
Invesco QQQ Trust
QQQ
$369B
| $2.55M | 0.06% |
7,993
-7,310
| -48% | -$2.33M |
|
243
iShares MSCI Canada ETF
EWC
$3.24B
| $2.5M | 0.06% |
73,460
-7,700
| -9% | -$262K |
|
|
SAGE
244
DELISTED
Sage Therapeutics
SAGE
| $2.45M | 0.06% |
33,500
| – | – |
|
245
Take-Two Interactive
TTWO
$45.7B
| $2.45M | 0.06% |
13,909
-6,275
| -31% | -$1.11M |
|
246
Otis Worldwide
OTIS
$34.5B
| $2.44M | 0.06% |
+35,000
| New | +$2.44M |
|
247
Q32 Bio
QTTB
$21.7M
| $2.42M | 0.06% |
14,306
| – | – |
|
248
Arrowhead Research
ARWR
$3.83B
| $2.38M | 0.06% |
37,300
| – | – |
|
249
Neurocrine Biosciences
NBIX
$14.3B
| $2.35M | 0.06% |
24,900
| – | – |
|
250
Marsh & McLennan
MMC
$99.2B
| $2.32M | 0.06% |
19,100
| – | – |
|